Twist Bioscience President and COO Patrick Finn Completes Mandatory Sale of 2,238 Shares to Cover Tax Withholding

Details of Insider Transaction and Share Sale Mechanism

According to the disclosure, Patrick John Finn, serving as President and COO of Twist Bioscience, completed a sale of 2,238 shares at $93.893 per share on July 23, 2026. This sale was a mandatory "sell to cover" transaction designed to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs). Such transactions are standard practice for companies to assist executives in managing tax liabilities triggered by equity award vesting. The sale price of $93.893 per share was the basis for this transaction.

The filing clarifies that the sale was not a discretionary trade by Finn but was mandated by Twist Bioscience’s equity incentive plans to fulfill tax withholding requirements. This distinction is crucial for investors analyzing insider trading, as mandatory tax-related sales differ from voluntary equity dispositions. The company’s equity plan automatically triggers withholding calculations upon vesting events, sourcing the necessary funds through coordinated stock sales rather than requiring executives to provide cash.

Finn’s Beneficial Ownership After the Transaction

Following the sale of 2,238 shares, Finn’s beneficial ownership in Twist Bioscience stands at 272,566 shares held directly. This substantial retained stake highlights his continued financial alignment with shareholder interests and the company’s long-term performance. Direct ownership of this magnitude indicates ongoing exposure to Twist Bioscience’s operational and strategic outcomes.

The filing specifies that Finn’s shares are held directly, without intermediaries, which is significant in corporate governance. Direct beneficial ownership reflects clear alignment between executive financial interests and company performance, as the executive fully bears the economic impact of stock price fluctuations.

Context of Vesting and Equity Incentive Plan

The sale was triggered by the vesting of restricted stock units, a common form of long-term equity compensation in the biotech and life sciences industries. When RSUs vest, they convert into common shares, and recipients incur income tax liabilities on the vested value. Twist Bioscience has elected to satisfy these withholding obligations through coordinated share sales rather than requiring executives to pay taxes in cash.

This "sell to cover" approach simplifies tax compliance for both the company and executives. It avoids the need for Finn to liquidate other assets or secure external financing to meet tax obligations, streamlining the post-vesting process. The transaction does not reflect Finn’s discretionary investment decisions but is a mandatory compliance measure under company policy.

Executive Compensation and Trading Patterns

As President and COO, Finn holds a senior leadership role at Twist Bioscience and typically receives significant equity compensation as part of his remuneration package. The vesting schedules and volumes of RSUs granted aim to incentivize long-term retention and align executive pay with shareholder value creation over multiple years.

The July 23, 2026 transaction is a routine execution of the company’s equity plan mechanics, not a signal of Finn’s personal trading strategy. Investors often differentiate between discretionary insider sales, which might indicate concerns about valuation or prospects, and mandatory tax-driven sales, which occur irrespective of market conditions or executive sentiment. The filing’s clear statement that the sale was mandated and not discretionary provides important context for analysts.

Officer Status and Reporting Details

The filing confirms Patrick John Finn’s role as President and COO of Twist Bioscience Corporation, placing him among the company’s top executives responsible for strategic and operational management. As a Section 16 reporting person, Finn’s securities transactions are publicly disclosed and subject to regulatory oversight. His substantial shareholding and executive status demonstrate both formal authority and significant personal financial exposure to the company’s performance.

The filing was executed by Kendra Fox as Attorney-in-Fact for Finn, indicating standard administrative procedures were followed for regulatory compliance and documentation.

Tax Withholding Procedures and Equity Plan Structure

Twist Bioscience’s equity incentive plan includes an election to satisfy tax withholding obligations through coordinated share sales. When RSUs vest and convert to common stock, a portion of shares is automatically sold at the prevailing market price—$93.893 in this instance—to cover estimated income tax liabilities. This mechanism ensures tax obligations are met promptly without requiring executives to provide separate funds.

These "sell to cover" arrangements are governed by the equity plan and tax regulations, simplifying the vesting process and administrative burden. The filing’s explicit note that these sales are not discretionary trades distinguishes them from independent trading decisions that could indicate executive sentiment.

Regulatory Compliance and Insider Trading Disclosure

Finn’s transaction disclosure complies with securities laws mandating officers, directors, and significant shareholders to report changes in beneficial ownership. The filing was submitted on July 27, 2026, within the required reporting timeframe, with the transaction occurring on July 23, 2026. This transparency supports SEC oversight and market integrity by providing detailed information on insider trading activity.

The comprehensive filing includes transaction date, share quantity, price, and post-transaction ownership, creating a public record of Finn’s equity position. The certification language underscores the accuracy and legal responsibility associated with the disclosure.

Ownership Threshold and Executive Alignment

Although Finn is not reported as a 10 percent beneficial owner, his role as President and COO makes him a Section 16 reporting person. His direct ownership of 272,566 shares reflects a meaningful economic stake, indicating alignment with shareholder interests. Investors often view such holdings as a sign of executive confidence in the company’s future.

This ownership baseline provides context for future equity transactions by Finn, enabling market observers to assess changes in his exposure and potential signals about company prospects.

Market Conditions and Transaction Timing

The sale occurred on July 23, 2026, at a price of $93.893 per share, reflecting the market price at the time of the mandatory transaction. The timing aligns with the company’s equity plan vesting schedule. The filing does not disclose the total RSUs vested on this date, only the shares sold to cover tax withholding.

While investors often consider insider sale timing relative to market conditions, mandatory tax-driven sales are dictated by vesting schedules rather than executive discretion. The transaction price may differ from current or future trading levels depending on subsequent market and company developments.